The pneumococcal polysaccharide vaccine (PPV) is currently recommended for older adults and high-risk subjects, including patients with chronic obstructive pulmonary disease (COPD) and asthma.

In addition to increasing vaccine coverage in older adults, they need to monitor the changing epidemiology of pneumococcal serotypes causing invasive disease. [134] In the face of these changes ...

Prevenar 13 is a mixture of the outer sugar coating (polysaccharide ... child have ever had an allergic reaction to pneumococcal or diphtheria vaccines, or any of the ingredients listed at ...

polysaccharide-based jab Pneumovax 23. Sanofi's new challenger is billed as a "next-generation" pneumococcal conjugate vaccine that, according to the company, is the first candidate with more than ...

An important step is getting pneumococcal vaccination if it's recommended for you. This vaccine helps protect against pneumococcal disease, including, pneumococcal pneumonia, bloodstream infection ...

Amid the growing importance of pneumococcal vaccination to prevent pneumonia during the change of seasons, confusion is ...

Participants were randomized to receive a single dose of either one of three lots of CAPVAXIVE or PPSV23 (pneumococcal 23-valent polysaccharide vaccine). Results from the study include ...

The rivalry between Pfizer and MSD in pneumococcal ... on an older polysaccharide technology that does not stimulate the immune response as strongly as the newer conjugate vaccines.

report_id=VIT669 What factors are influencing the growth of the 23 Valent Pneumococcal Polysaccharide Vaccine Market over the forecast period? What is the competitive landscape in Vietnam 23 Valent ...

Pneumococcal vaccine polyvalent ... patients received either meningococcal polysaccharide serogroup A or placebo. The 6- and 12-valent vaccines achieved a protective efficacy of 76% and 92% ...

Merck MRK announced that the European Commission (“EC”) has approved its 21-valent pneumococcal conjugate vaccine (“PCV”), Capvaxive, for the prevention of invasive pneumococcal disease ...

No serious adverse events were considered to be related to the study vaccines. Post-dose 3, the VAX-24 Mid dose met target precedent Phase 2 non-inferiority (NI) criteria on relative ...